REGN Regeneron Pharmaceuticals Inc.

439.37
-3.19  -1%
Previous Close 442.56
Open 443.20
Price To book 8.53
Market Cap 47079472220
Shares 107,152,223
Volume 545,166
Short Ratio 2.77
Av. Daily Volume 734,123

SEC filingsSee all SEC filings

  1. 8-K/A [Amend] - Current report 171083245
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171002843
  3. 8-K - Current report 171002804
  4. 8-K - Current report 17910325
  5. S-8 - Securities to be offered to employees in employee benefit plans 17906391

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

sBLA Approval announced April 25, 2017.
Praluent (alirocumab)
High low-density lipoprotein (LDL) cholesterol
Phase 3 trial to be initiated 3Q 2017.
Dupixent (dupilumab)
Atopic dermatitis 6-11 year-olds
Phase 3 trial initiated 2Q 2017.
Dupixent (dupilumab)
Atopic dermatitis 12-17 year-olds
Phase 3 data due 1Q 2018.
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
Phase 3 enrolling.
REGN2810
Non-small cell lung cancer (NSCLC)
Phase 2 enrolling as of September 2017. BLA filing due 1Q 2018 pending data.
REGN2810
Basal cell carcinoma
Phase 3 trial initiated using only lower doses from Phase 2/3 trial.
Fasinumab
Moderate-to-severe osteoarthritis pain of the hip or knee
Phase 3 data released August 14, 2017 - primary endpoint not met.
REGN2222
Respiratory syncytial virus (RSV)
Phase 3 continues to enroll - August 2017.
EYLEA - PANAROMA
Nonproliferative Diabetic Retinopathy
Phase 3 ongoing.
EYLEA - PROTOCOL-W
Diabetic Retinopathy
Phase 3 enrollment commenced 2Q 2017.
Dupixent (dupilumab)
Asthma - 6-11 year-olds
Phase 3 data released September 11, 2017 - primary endpoints met. 46% improvement after 52 weeks in 300 mg group. sBLA filing due by end of 2017.
Dupixent (dupilumab) - LIBERTY ASTHMA QUEST
Asthma
Phase 3 trial commenced 4Q 2016.
Dupixent (dupilumab)
Nasal polyps
Phase 2b placed on clinical hold. Phase 3 trial to be initiated that excludes patients with advanced osteoarthritis 2H 2017.
Fasinumab
Osteoarthritis and chronic low back pain
Pivotal Phase 2/3 trial ongoing.
REGN2810
Cutaneous squamous cell carcinoma
Phase 2 trial to commence 1H 2017.
REGN2810
Non-small cell lung cancer (NSCLC)
Phase 2 enrollment completed 4Q 2016. Data due 2H 2017.
EYLEA + nesvacumab
Diabetic macular edema (DME)
Phase 2 data due 2H 2017.
EYLEA + nesvacumab
AMD - age-related macular degeneration
Phase 2 trial to commence 2H 2017.
Dupixent (dupilumab)
Food Allergy
Phase 2 data released May 4, 2017. Phase 3 trial to be initiated 1Q 2018.
Dupixent (dupilumab)
Eosinophilic esophagitis
Approved under priority review - March 28, 2017.
Dupixent (dupilumab)
Atopic dermatitis
CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.
Sarilumab
Rheumatoid arthritis

Latest News

  1. Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug
  2. Regeneron-Sanofi drug succeeds mid-stage study
  3. Sanofi/Regeneron's Dupixent Succeeds in Phase II Study
  4. Gilead Sciences on the Street: Analyst Recommendations in October
  5. UPDATE 1-Regeneron-Sanofi drug succeeds mid-stage study
  6. Aimmune teams with Regeneron, Sanofi on peanut allergy drug
  7. Regeneron-Sanofi throat infection drug succeeds key study
  8. 6 Top Biotech Companies In Innovation Earn Recognition In New Awards
  9. Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
  10. Regeneron Advances Science To Attack Arthritis, Eye Disease, More
  11. Dupixent May Be Strong Growth Driver for Sanofi in the Future
  12. Drugmakers Are Planning to Start a Phase 2 Trial to Cure Peanut Allergy
  13. Pres Trump believes he has the cure for Obamacare
  14. Dow's Merck Bails On Cholesterol Drug, Prodding Shares Down
  15. Regeneron to Report Third Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on November 8, 2017
  16. Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit
  17. Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis
  18. This Biotech Hit Record High; Could Undercut Regeneron In Eczema
  19. [$$] Ruling Goes Regeneron's Way
  20. Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : October 9, 2017